christmas around the world research paper how to write a concluding paragraph for a comparative essay innocence theme essay all quiet on the western front write book review essay why do we write thesis

MANCO Project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003651

MANCO AT A GLANCE

A 27-month EU-funded research project

MANCO – Monoclonal Antibodies against COVID-19 – is a 27-month EU research project funded under the Horizon 2020 programme. The MANCO project is coordinated by the Erasmus Medical Centre (EMC) based in The Netherlands. The project has started on 1st March 2020 and will last about 2 years.

Project Identity Card


MANCO:

Monoclonal Antibodies against
COVID-19

Grant Agreement N° 101003651

1st March 2020 – 31st May 2022


Project dates

1st March 2020
– 31st May 2022


Coordination

Erasmus Medical
Center (EMC),
Netherlands


Consortium

8 partners from
4 Countries :
Netherlands,
Germany,
Spain & France


Funded under
Horizon 2020

EU Contribution:
3M€

The MANCO consortium at a glance

MANCO is a collaborative research project bringing together a complementary and highly experienced group of 8 partners from 4 European countries (The Netherlands, Germany,
Spain and France) that will achieve the critical mass required to deliver the ambitious objectives of this research programme.

THE OVERALL CONCEPT OF THIS
COLLABORATIVE RESEARCH PROJECT

Overall, The MANCO project aims at contributing to the rapid international response against COVID-19, through preclinical and clinical evaluation of monoclonal antibodies against this coronavirus.

More specifically, MANCO will advance one lead (prophylactic and/ or therapeutic) monoclonal antibody into a Phase I clinical trial to be completed within two years from the start of the project, by leveraging clinical expertise, infrastructure and relevant network.

Logo_ManCo2

MANCO Project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003651